WikiMD logo

COVID-19 portal | Vitamin D | CDC | Vaccine | Ketogenic diet

WikiMD is the world's largest medical encyclopedia with
327,207 articles, 3,627,766 edits, & 32,959,007 views


Let food be thy medicine, and medicine be thy food - Hippocrates

Liraglutide

From WikiMD
Jump to navigation Jump to search
This page contains changes which are not marked for translation.

Other languages:
English

Information about Liraglutide

Liraglutide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents.

Liver safety of Liraglutide

There have been no published reports of hepatotoxicity attributed to liraglutide therapy.

Mechanism of action of Liraglutide

Liraglutide (lir" a gloo' tide) is a glucagon-like peptide-1 (GLP-1) analogue that acts like the native gastrointestinal hormone (incretin) to increase insulin secretion. Liraglutide reproduces the activity of GLP-1, binding to specific receptors on pancreatic beta cells and increasing insulin secretion, which can lead to improvement of glycemic control in patients with type 2 diabetes.

Recombinant DNA produced

Liraglutide is a recombinant DNA produced polypeptide that shares 97% homology to endogenous human GLP-1(7-37), which represents 20% of circulating GLP-1 activity in serum. Unlike GPL-1(7-37), however, liraglutide is resistant to DPP-4 degradation and thus has a prolonged duration of activity. Liraglutide, like other GLP-1 analogues, must be given parenterally.

FDA approval information for Liraglutide

Liraglutide was approved for use in the United States in 2010 and current indications are for management of glycemic control in adults with type 2 diabetes in combination with diet and exercise, with or without other oral hypoglycemic agents.

Brand name for Liraglutide

Liraglutide is available under the brand name Victoza for diabetes and Saxenda for weight loss in solution for subcutaneous injection in prefilled multidose pens (6 mg/mL).

Dosage and administration for Liraglutide

The typical initial dose is 0.6 mg once daily, which can be increased to a maximum of 1.8 mg daily for diabetes and 3 mg daily for weight loss.

Side effects of Liraglutide

Liraglutide is generally well tolerated, but side effects can be dose limiting and include nausea, vomiting, diarrhea, dizziness, headache, fatigue and rash.

Marketing

Novo Nordisk has made direct-to-consumer advertising of liraglutide in Sweden (May 2011), through a 6-page supplement in the free newspaper Metro. Although the name of the drug was not explicitly mentioned (this is illegal in the European Union), it could easily be identified through supplied information on dosage and pharmacodynamics.

See also

exenatide (Byetta)
albiglutide
taspoglutide

Antidiabetics

Cost and Coupons - Liraglutide

Reviews for Liraglutide

The article on Liraglutide is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


edit 

WikiMD Resources - Liraglutide


Help WikiMD:Join WikiMD as an an editor and help improve the page Liraglutide or others.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Other languages:
English

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Liraglutide">Liraglutide</a>

  • Individual results may vary for weight loss from our sponsors.